Pitango Venture Capital
11 Ha-Menofim St. Building B, Herzliya, 4672562, Israel
Overview
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech. With two offices in Israel, Pitango currently manages several venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
- Total investments
- 196
- Lead investments
- 71
- Investments · 12mo
- 8
- Active investors
- 11
Sector focus
- Banking
- DevOps
- Financial Services
- FinTech
- Health Care
- Information Technology
- Venture Capital
- Web3
Investment portfolio
- DriveNets
Participated · Series D · Jun 2026
DriveNets develops a disaggregated Network Cloud and Ethernet-based AI fabric designed to eliminate networking bottlenecks and maximize GPU utilization in large-scale AI clusters. Its solutions perform end-to-end networking optimizations across the AI stack and support heterogeneous, multi-vendor AI environments. The company works with accelerator and silicon partners such as AMD and Broadcom and systems partners including Dell and Supermicro, and its products power production networks for tier-1 operators like AT&T and Comcast. DriveNets reported more than $1 billion in secured business, has been cash-flow positive since 2025, and has raised $1 billion in total capital to date. Founded ten years ago and based in Ra'anana, Israel, the company positions its AI fabric to accelerate deployment, improve tokens-per-second, and lower cost-per-token for large AI deployments.
- Tomorrow.io
Participated · Series F · May 2026
Tomorrow.io positions itself as the world's leading Resilience Platform, combining a proprietary satellite constellation with a generative AI–integrated forecasting engine to deliver weather intelligence. The company says it operates a fully operational proprietary satellite constellation and leverages next-generation space technology, advanced AI, and proprietary weather modeling. Tomorrow.io is deploying DeepSky, described as the world's first AI-native weather satellite constellation, and aims to expand its space-based observation network. Its platform is used to provide real-time, actionable resilience intelligence and is trusted by six of the top ten Fortune 500 companies. The company has been recognized as a TIME 100 Most Influential Company and a Fast Company Most Innovative Company. The recent expansion of its Series F to $210 million is intended to accelerate its AI capabilities and further develop its agentic platform.
- Altair Semiconductor
Led · Equity · Apr 2026
Altair Semiconductor has spent about 20 years as a supplier of cellular IoT chips, with its LTE-M and NB‑IoT modems used in smart meters, logistics trackers and some wearables. Following a spin-out from Sony Semiconductor Solutions, it regained independence and secured $50 million in new funding to support a strategic pivot into 5G IoT. The company is developing and testing the ALT1550 modem based on 5G eRedCap technology aimed at industrial and large-scale low‑power deployments. Altair positions eRedCap as a cost- and power-efficient way to bring industrial and legacy devices onto 5G networks. Management says customer support and service will continue uninterrupted through the transition. No revenue, user, or valuation metrics were provided in the articles.
- Altesa
Participated · Series B · Feb 2026
Altesa BioSciences is focused on treating chronic lung diseases by targeting the viral infections that trigger respiratory exacerbations. Its lead oral candidate, vapendavir, is designed to neutralise rhinovirus—the predominant cause of exacerbations in millions of COPD and asthma patients. In a recently completed Challenge Study, vapendavir improved upper and lower airway symptoms, shortened illness duration, lowered inflammatory markers, and preserved small-airway function relative to placebo. The company projects that, if approved, vapendavir could prevent up to 50 % of COPD exacerbations, improving quality of life and reducing healthcare costs. Altesa plans to launch the 900-patient Phase 2b CARDINAL study in the US and UK in Q2 2026 to further evaluate safety and efficacy. Led by former U.S. Assistant Secretary of Health Brett P. Giroir, M.D., and guided by a board chaired by Moncef Slaoui, Ph.D., the team includes seasoned executives with backgrounds at GSK and other major firms. The firm is headquartered in Atlanta and advocates for expanded access to modern respiratory diagnostics and therapeutics in underserved communities.
- Adaptive6
Participated · Series A · Jan 2026
Adaptive6 offers a Cloud Cost Governance and Optimization (CCGO) platform that treats overspending in cloud environments the way modern security tools treat vulnerabilities. Its proprietary engine continuously scans AWS, GCP, Azure, and popular SaaS/PaaS services, traces each inefficiency back to the exact line of code with its Cloud-to-Code technology, and then auto-generates fixes that can be applied with one click or delivered as pull requests. The system also enforces preventative policies in Git and CI/CD pipelines, allowing engineers to catch cost issues before deployment and achieve shift-left governance. Early enterprise adoption is strong: dozens of Fortune 500 and Global 2000 companies, including Bayer and Ticketmaster, are already customers and report 15–35 % reductions in total cloud spend, with individual fixes sometimes saving more than $1 million annually. Adaptive6 positions itself as the first end-to-end platform for cloud cost governance, combining detection, prevention, and automated remediation. The founding team—Unit 8200 veterans Aviv Revach, Omer Müller, and Eyal Brosh—brings deep FinOps and cloud-security expertise. To date the company has secured $44 million in venture financing, providing a solid capital base for continued product expansion and customer growth.